Johnson & Johnson (NYSE:JNJ) Shares Acquired by Aurora Private Wealth Inc.

Posted by Defense World Staff on Jun 20th, 2023

Aurora Private Wealth Inc. grew its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,521 shares of the company’s stock after purchasing an additional 194 shares during the quarter. Johnson & Johnson makes up 1.1% of Aurora Private Wealth Inc.’s investment portfolio, making the stock its 22nd largest position. Aurora Private Wealth Inc.’s holdings in Johnson & Johnson were worth $1,011,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.2% in the 3rd quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after buying an additional 2,815,655 shares during the last quarter. State Street Corp grew its position in shares of Johnson & Johnson by 0.6% in the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock valued at $23,178,548,000 after buying an additional 803,013 shares during the last quarter. Moneta Group Investment Advisors LLC grew its position in shares of Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock valued at $8,456,643,000 after buying an additional 294,671 shares during the last quarter. Finally, Morgan Stanley grew its position in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. 67.57% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the business’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at $10,549,440. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.20% of the stock is owned by insiders.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Raymond James dropped their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 19th. Citigroup started coverage on shares of Johnson & Johnson in a research report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price objective on the stock. StockNews.com started coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating on the stock. Credit Suisse Group raised their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a research report on Friday, May 5th. Finally, Guggenheim started coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They set a “neutral” rating and a $161.00 price objective on the stock. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $171.57.

Johnson & Johnson Stock Up 0.3 %

JNJ stock opened at $164.23 on Tuesday. The stock has a market capitalization of $426.79 billion, a PE ratio of 34.36, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The company has a fifty day moving average of $160.73 and a 200-day moving average of $163.78. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. The firm had revenue of $24.75 billion for the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.67 earnings per share. As a group, analysts expect that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd were issued a dividend of $1.19 per share. The ex-dividend date was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a yield of 2.90%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is currently 99.58%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.